Hepatocellular carcinoma recurrence after liver transplant: An Australian single-centre study

Table 2 Predictors of post-transplant hepatocellular carcinoma recurrence

Variable	Univariate		Multivariate
	HR (95%CI)	P value	HR (95%CI)	P value
Age (years)	0.98 (0.91-1.05)	0.62
Male	1.55 (0.32-7.32)	0.57
Female	0.64 (0.13-3.03)	0.58
Obesity	0.56 (0.11-2.65)	0.46
Overweight	2.07 (0.58-7.35)	0.25
Histology pre-transplant performed	2.10 (0.60-7.31)	0.24
Explant tumour characteristics
Viable HCC on explant	0.72 (0.09-5.7)	0.76
Number of viable lesions
1	0.55 (0.05-5.3)	0.60
2-3	0.44 (0.04-4.8)	0.50
> 3	2.0 (0.22-17.9)	0.53
Max diameter of viable tumour (mm)	1.02 (0.98-1.06)	0.19
Sum of diameters (mm)	1.01 (0.96-1.0)	0.64
Macrovascular invasion	12.2 (1.47-102)	0.02	18.6 (1.98-174)	0.01
Microvascular invasion	1.75 (0.43-7.04)	0.42
Tumour differentiation
Well	1.52 (0.17-13.1)	0.58
Moderate	0.96 (0.10-8.6)	0.47
Poor	1.87 (1.63-80.5)	0.12
Serum markers
Highest Pre-op alpha-fetoprotein	1.00 (0.64-1.00)	0.64
neutrophil-lymphocyte ratio	0.90 (0.66-1.22)	0.51
Waiting time (days)	1.00 (0.99-1.00)	0.55
Cold Ischemia time (minutes)	1.00 (0.97-1.03)	0.70
Wait time from HCC diagnosis to liver transplantation
< 6 months	0.60 (0.17-2.15)	0.44
> 6 months	1.64 (0.46-5.85)	0.43

Results based on univariate and multivariate risk regression models. HCC: Hepatocellular carcinoma; HR: Hazard ratio.